Lecithin / TIMP1 Cancer Research Results

LEC, Lecithin: Click to Expand ⟱
Features:

Lecithin — a heterogeneous mixture of phospholipids (primarily phosphatidylcholine [PC], phosphatidylethanolamine [PE], phosphatidylinositol [PI], phosphatidylserine [PS]) derived from soy, sunflower, egg yolk, or marine sources. Used as a dietary supplement, emulsifier, and drug-delivery excipient.

Primary mechanisms (conceptual rank):
1) Structural membrane phospholipid supply (↑ PC pool; lipid remodeling)
2) Lipoprotein assembly & lipid transport (hepatic VLDL export; choline donation)
3) Indirect methyl donor contribution (via choline → betaine → SAM axis)
4) Delivery platform (liposomes/nanocarriers; not intrinsic cytotoxicity)

Bioavailability / PK relevance: Orally digested to lysophospholipids + choline; re-esterified and incorporated into lipoproteins/cell membranes. Systemic effects reflect nutrient flux, not direct pharmacologic signaling.

In-vitro vs oral exposure: Many membrane or apoptosis effects seen in vitro are concentration-dependent and not reflective of typical dietary intake.

Clinical evidence status: Nutritional supplement; evidence strongest for hepatic lipid metabolism and choline deficiency states. No validated anti-cancer indication.

Lecithin a phospholipid-rich compound (often derived from soy or sunflower), can enhance the bioavailability of certain lipophilic (fat-soluble) and amphipathic compounds by improving their solubility, absorption, and cellular uptake.

Supplements and Compounds with Improved Bioavailability via Lecithin
Curcumin Up to 20–30x better absorption in some formulations
Quercetin
Resveratrol
Silybin (from milk thistle)
Green tea catechins, EGCG Lecithin helps stabilize and protect catechins during digestion
Boswellic acids
Coenzyme Q10 (CoQ10)
Omega-3 fatty acids
Vitamin D, E, A, K (Fat-soluble vitamins)
Alpha-lipoic acid (ALA)
black seed oil (Nigella sativa) and its key active compound, thymoquinone.



Lecithin — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Membrane phospholipid pool (PC/PE balance) ↑ substrate availability ↑ membrane integrity G Structural lipid incorporation Supplies phospholipids; tumors already upregulate choline kinase/PC synthesis (Warburg-lipid coupling).
2 Choline → SAM methylation axis ↑ (substrate supply) ↑ (physiologic support) G Methyl donor availability Indirectly feeds one-carbon metabolism; impact depends on baseline methyl status.
3 Lipid transport (VLDL assembly; hepatic export) ↔ (indirect) ↑ (hepatoprotection) G Improved lipid handling Supports prevention of fatty liver in deficiency states; not tumor-targeted.
4 PI3K/AKT/mTOR (lipid availability coupling) ↔ / ↑ (context-dependent) ↔ G Anabolic lipid support Not a direct activator; increased lipid substrate may support proliferative metabolism in certain contexts.
5 ROS / redox balance ↔ ↔ / ↓ (membrane stabilization) P/R Membrane oxidative buffering Phospholipids can influence membrane peroxidation susceptibility; not a primary redox drug.
6 NRF2 axis ↔ ↔ R/G No primary modulation No consistent evidence of direct NRF2 activation or inhibition.
7 Ferroptosis susceptibility (PUFA content dependent) ↑ or ↓ (composition-dependent) ↔ R/G Membrane lipid remodeling High PUFA phospholipids may increase ferroptotic vulnerability; saturated profiles may reduce it.
8 HIF-1α / Warburg linkage ↔ (indirect metabolic support) ↔ G Lipid–glycolysis coupling Tumors with high choline metabolism may utilize supplied substrates; not inhibitory.
9 Ca²⁺ signaling (membrane microdomain effects) ↔ (subtle; composition-dependent) ↔ P/R Membrane fluidity modulation Altered phospholipid ratios can affect membrane protein function; not a defined pharmacologic axis.
10 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Nutritional, not cytotoxic No evidence of direct anti-cancer efficacy; may theoretically support lipid-dependent tumors depending on context.

TSF legend:
P: 0–30 min (membrane incorporation effects)
R: 30 min–3 hr (acute metabolic signaling shifts)
G: >3 hr (lipid remodeling / phenotype outcomes)
TIMP1, Tissue Inhibitor of Metalloproteinases-1: Click to Expand ⟱
Source:
Type:
A protein that plays a role in the regulation of matrix metalloproteinases (MMPs), which are enzymes involved in the breakdown of the extracellular matrix.
TIMP-1 is overexpressed in various types of cancer, including breast, lung, colon, and prostate cancer. High levels of TIMP-1 have been associated with poor prognosis and increased risk of metastasis (cancer spread) in some cancers.
Scientific Papers found: Click to Expand⟱
1792- CUR,  LEC,    Chondroprotective effect of curcumin and lecithin complex in human chondrocytes stimulated by IL-1β via an anti-inflammatory mechanism
- in-vitro, Arthritis, RAW264.7 - NA, NA, HCC-38
*Inflam↓, *NF-kB↓, *iNOS↓, *COX2↓, *NO↓, *PGE2↓, *MMPs↑, *TIMP1↑, *BioEnh↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Cell Death ⓘ

iNOS↓, 1,  

Migration ⓘ

MMPs↑, 1,   TIMP1↑, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   PGE2↓, 1,  

Drug Metabolism & Resistance ⓘ

BioEnh↑, 1,  
Total Targets: 9

Scientific Paper Hit Count for: TIMP1, Tissue Inhibitor of Metalloproteinases-1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:114  Target#:307  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page